EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Parasite‐Derived IL‐33 Inhibitors Prevent Bleomycin‐Induced Lung Fibrosis

Samuele Di Carmine, Tania Frangova, Suzanne H Hodge, Danielle J Smyth iD, Tera Birchall, Josh Richards, Ian Newton iD, Sarah Kelly, Alice R Savage iD, E Suzanne Cohen, J Simon C Arthur iD, Henry J McSorley iD

European Journal of Immunology · 2026-10 · 56 (10)

DOI: 10.1002/eji.70291 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Immunology, online erschienen am 08.10.2026. Verfasst von Samuele Di Carmine und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cell Signalling and Immunology, School of Life Sciences, University of Dundee, Dundee, UK. Hauptthemen laut MEDLINE: Interleukin-33, Nematospiroides dubius, Strongylida Infections, Idiopathic Pulmonary Fibrosis. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Scotland and AstraZeneca Ltd PhD studentship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Idiopathic pulmonary fibrosis (IPF) is a progressive lung‐scarring disease in which epithelial injury, consequent release of alarmins such as interleukin (IL)‐33, and immune activation contribute to extracellular matrix deposition. The intestinal helminth Heligmosomoides polygyrus bakeri ( Hpb ) secretes immunomodulators that suppress type 2 immunity, including HpARI2, which binds IL‐33, and HpBARI_Hom2, which blocks the IL‐33 receptor ST2. Here, we test this parasite‐derived dual blockade strategy in the bleomycin (BLM) mouse model, moving from live Hpb infection to administration of total Hpb excretory/secretory products (HES), and finally administering recombinant HpARI2 and HpBARI_Hom2 proteins. Hpb infection and HES treatment prevented BLM‐induced lung fibrosis when administered during the early inflammatory phase. Recombinant HpARI2+HpBARI_Hom2 reproduced this protection, reduced collagen deposition and hydroxyproline accumulation, and dampened ILC2, eosinophil, macrophage, and neutrophil responses. In contrast, HES or HpARI2+HpBARI_Hom2 administration failed to reverse established fibrosis when administered later in the model. Similarly, administration of the IL‐33trap fusion protein could replicate these effects, suppressing fibrosis when administered in the early inflammatory, but not later fibrotic phases of this model. These findings identify parasite‐derived inhibition of the IL‐33 axis as a defined molecular mechanism by which helminth products can prevent early inflammatory fibrogenesis, while also demonstrating that IL‐33 blockade is unlikely to reverse established lung scarring.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-33Nematospiroides dubiusStrongylida InfectionsIdiopathic Pulmonary FibrosisHelminth ProteinsPulmonary FibrosisAnimalsBleomycinMiceDisease Models, AnimalInterleukin-1 Receptor-Like 1 ProteinMice, Inbred C57BLHumansLung

Stichwörter der Autor:innen

Heligmosomoides polygyrus bakeriIL‐33IL‐33 blockadeIdiopathic pulmonary fibrosistype 2 inflammation

Substanzen

Interleukin-33BleomycinIl33 protein, mouseInterleukin-1 Receptor-Like 1 ProteinHelminth ProteinsIl1rl1 protein, mouse

Autor:innen und Institutionen

  • Division of Cell Signalling and Immunology, School of Life Sciences, University of Dundee, Dundee, UK.
  • Bioscience Asthma and Skin Immunity, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.

ORCID-Profile: Danielle J Smyth, Ian Newton, Alice R Savage, J Simon C Arthur, Henry J McSorley

Förderung

  • Medical Research Scotland and AstraZeneca Ltd PhD studentship

Zitieren

APA

Carmine, S. D., Frangova, T., Hodge, S. H., Smyth, D. J., Birchall, T., Richards, J., Newton, I., Kelly, S., Savage, A. R., Cohen, E. S., Arthur, J. S. C., & McSorley, H. J. (2026). Parasite‐Derived IL‐33 Inhibitors Prevent Bleomycin‐Induced Lung Fibrosis. European Journal of Immunology, 56(10). https://doi.org/10.1002/eji.70291

Vancouver

Carmine SD, Frangova T, Hodge SH, Smyth DJ, Birchall T, Richards J, et al. Parasite‐Derived IL‐33 Inhibitors Prevent Bleomycin‐Induced Lung Fibrosis. European Journal of Immunology. 2026;56(10). doi:10.1002/eji.70291

BibTeX
@article{Carmine2026,
  author = {Carmine, Samuele Di and Frangova, Tania and Hodge, Suzanne H and Smyth, Danielle J and Birchall, Tera and Richards, Josh and Newton, Ian and Kelly, Sarah and Savage, Alice R and Cohen, E Suzanne and Arthur, J Simon C and McSorley, Henry J},
  title = {Parasite‐Derived IL‐33 Inhibitors Prevent Bleomycin‐Induced Lung Fibrosis},
  journal = {European Journal of Immunology},
  year = {2026},
  volume = {56},
  number = {10},
  doi = {10.1002/eji.70291}
}
Kostenlos starten →